Spots Global Cancer Trial Database for DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Official Title: Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma
Study ID: NCT02487017
Study Description
Brief Summary: Evaluation of DC-CIK cells combined TACE treatment for HCC
Detailed Description: 60 patients with Hepatocellular Carcinoma, who had received Transcatheter Arterial Chemoembolization (TACE) , will be randomly divided into group A (receive DC-CIK+ TACE treatment) or group B (just receive TACE), and the randomize ratio will be 1:1.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yantai City Hospital for Infectious Diseases, Yantai, Shandong, China
Contact Details
Name: Xiangzhong Liu, Professor
Affiliation: Yantai City Hospital for Infectious Diseases Immunotherapy center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
